Posts tagged pharmaceutical
The pharmaceutical industry is not a naturally grown health industry, but an artificially created investment business based on the deceptive promise to deliver health. The marketplace of the pharmaceutical industry is your body – but only as long as it is sick. Prevention, root cause treatment and, above all, eradication of diseases decrease or destroy the pharmaceutical markets and are, therefore, not in the interest of this industry. The great majority of pharmaceutical drugs have no proven efficacy and are merely symptom oriented. The basis of the enormous profits of this industry is not effectively fighting diseases, but the patent royalties of newly synthesized molecules unknown to the human body. Because most pharmaceutical drugs are synthetic molecules, they are toxic to the human body and frequently cause serious side effects, new diseases or even death. To hide this global deception scheme, the pharmaceutical industry spends more money to disguise its deceptive business scheme than for research. This money is used for thorough advertising, lobbying and other measures. Vitamins and other natural health therapies are threatening the very basis of the pharmaceutical business for two reasons: First, they prevent or treat the root cause of today’s most common diseases. Second, they are generally not patent-able and therefore have low profit margins. Natural health therapies and the pharmaceutical “business with disease” are incompatible and cannot coexist. The precondition for the long-term prosperity of the pharmaceutical industry is the elimination of natural therapies.
Disease of Hype – Big Pharma Spends More On Advertising Than Research And Development, Study Finds [07Jan08]
Here is a healthy scientific critique of an industry that pays less in the science than of its own advertising.
A new study by two York University researchers estimates the U.S. pharmaceutical industry spends almost twice as much on promotion as it does on research and development, contrary to the industry’s claim.
The researchers’ estimate is based on the systematic collection of data directly from the industry and doctors during 2004, which shows the U.S. pharmaceutical industry spent 24.4% of the sales dollar on promotion, versus 13.4% for research and development, as a percentage of US domestic sales of US$235.4 billion.
“In our paper, we make the case for the need for a new estimate of promotional expenditures by the U.S. pharmaceutical industry,” says Gagnon. “We then explain how we used proprietary databases to construct a revised estimate and finally, we compare our results with those from other data sources to argue in favor of changing the priorities of the industry.”
The study is important because it provides the most accurate image yet of the promotional workings of the pharmaceutical industry, says Lexchin.
The authors focused their study on the United States because it is the only country in which information is available for all of the major promotion categories, and it is also the largest market for pharmaceuticals in the world, representing approximately 43% of global sales and global promotion expenditures.
As well, note the authors, the number of meetings for promotional purposes has dramatically increased in the U.S. pharmaceutical industry, jumping from 120,000 in 1998 to 371,000 in 2004, further supporting their findings that the U.S. pharmaceutical industry is marketing-driven.